Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 82 of the 95 references it cites were found in a registry or an index; 29 of the 34 sources its claims cite were checked for support.
Abstract
OBJECTIVES: The rapid spread of the SARS-CoV-2 Omicron variant has raised concerns regarding waning vaccine-induced immunity and durability. We evaluated protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant and its sublineages. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic databases and other resources (PubMed, Embase, CENTRAL, MEDLINE, CINAHL PLUS, APA PsycINFO, Web of Science, Scopus, ScienceDirect, MedRxiv and bioRxiv) were searched until December 2022. STUDY ELIGIBILITY CRITERIA: We included studies that assessed the effectiveness of mRNA vaccine booster doses against SARS-CoV-2 infection and severe COVID-19 outcomes caused by the subvariant. DATA EXTRACTION AND SYNTHESIS: Estimates of vaccine effectiveness (VE) at different time points after the third-dose and fourth-dose vaccination were extracted. Random-effects meta-analysis was used to compare VE of the third dose versus the primary series, no vaccination and the fourth dose at different time points. The certainty of the evidence was assessed by Grading of Recommendations, Assessments, Development and Evaluation approach. RESULTS: This review included 50 studies. The third-dose VE, compared with the primary series, against SARS-CoV-2 infection was 48.86% (95% CI 44.90% to 52.82%, low certainty) at ≥14 days, and gradually decreased to 38.01% (95% CI 13.90% to 62.13%, very low certainty) at ≥90 days after the third-dose vaccination. The fourth-dose VE peaked at 14-30 days (56.70% (95% CI 50.36% to 63.04%), moderate certainty), then quickly declined at 61-90 days (22% (95% CI 6.40% to 37.60%), low certainty). Compared with no vaccination, the third-dose VE was 75.84% (95% CI 40.56% to 111.12%, low certainty) against BA.1 infection, and 70.41% (95% CI 49.94% to 90.88%, low certainty) against BA.2 infection at ≥7 days after the third-dose vaccination. The third-dose VE against hospitalisation remained stable over time and maintained 79.30% (95% CI 58.65% to 99.94%, moderate certainty) at 91-120 days. The fourth-dose VE up to 60 days was 67.54% (95% CI 59.76% to 75.33%, moderate certainty) for hospitalisation and 77.88% (95% CI 72.55% to 83.21%, moderate certainty) for death. CONCLUSION: The boosters provided substantial protection against severe COVID-19 outcomes for at least 6 months, although the duration of protection remains uncertain, suggesting the need for a booster dose within 6 months of the third-dose or fourth-dose vaccination. However, the certainty of evidence in our VE estimates varied from very low to moderate, indicating significant heterogeneity among studies that should be considered when interpreting the findings for public health policies. PROSPERO REGISTRATION NUMBER: CRD42023376698.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 50 real-world studies found that third- and fourth-dose mRNA COVID-19 boosters protect against Omicron infection and symptomatic disease but protection wanes over time. Protection against severe outcomes such as hospitalisation and death remained substantial for at least 6 months, though certainty of evidence ranged from very low to moderate.
Key findings
- Compared with the primary series, third-dose VE against SARS-CoV-2 infection was 48.86% (95% CI 44.90% to 52.82%, low certainty) at ≥14 days, declined to 38.01% (95% CI 13.90% to 62.13%, very low certainty) at ≥90 days, and fell to 16% (95% CI 12.40% to 19.60%, low certainty) at ≥150 days.
- Fourth-dose VE against infection peaked at 14–30 days at 56.70% (95% CI 50.36% to 63.04%, moderate certainty) and declined to 22% (95% CI 6.40% to 37.60%, low certainty) at 61–90 days.
- Compared with no vaccination, third-dose VE against hospitalisation remained stable and was 79.30% (95% CI 58.65% to 99.94%, moderate certainty) at 91–120 days; fourth-dose VE up to 60 days was 67.54% (95% CI 59.76% to 75.33%, moderate certainty) for hospitalisation and 77.88% (95% CI 72.55% to 83.21%, moderate certainty) for death.
- Third-dose VE compared with no vaccination was 75.84% (95% CI 40.56% to 111.12%, low certainty) against BA.1 infection and 70.41% (95% CI 49.94% to 90.88%, low certainty) against BA.2 infection at ≥7 days.
Methods
- Systematic review and meta-analysis registered in PROSPERO (CRD42023376698), reported per Cochrane and PRISMA guidelines; databases including PubMed, Embase, CENTRAL, MEDLINE, CINAHL PLUS, APA PsycINFO, Web of Science, Scopus, ScienceDirect, MedRxiv and bioRxiv were searched until December 2022.
- Included 50 studies (28 case–control, 22 cohort) assessing mRNA vaccine booster effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes caused by Omicron and its sublineages; no RCTs were identified.
- Random-effects meta-analysis pooled VE at specific and open-ended time points after third- and fourth-dose vaccination; heterogeneity was assessed with I², publication bias with funnel plots and Egger’s tests, and certainty of evidence with GRADE.
Limitations
- The paper states that most pooled estimates were based on a limited number of studies with 6-month follow-up after the last booster, so the impact of waning beyond these periods is unknown.
- The paper states high statistical heterogeneity between studies, predominantly US/European settings, mRNA-vaccine-specific findings, and possible risk of bias, publication bias, and small-study effects; certainty for infection and symptomatic infection was very low to moderate.
- Evident from the text: fourth-dose analyses were restricted to older people (≥60 years), several time-point estimates came from only one or two studies, and no RCTs were included, so causal inference and generalisability are limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 4 Not checked · 96 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“however, none have assessed the magnitude and duration of protection conferred by booster doses of mRNA vaccines, particularly for the fourth dose, for a comprehensive range of COVID-19 outcomes caused by the Omicron subvariant and its sublineages.”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Introduction
What the sources say
- Supportedcites [11] sourceExperimental — accuracy not yet measured
This paper is a systematic review of COVID-19 vaccine effectiveness, so it fits the citing sentence’s list of reviews. Its Methods (Data analysis; page not provided) focus on protection after the primary vaccine series, and its Discussion (page not provided) says all included studies preceded the emergence of Omicron. It therefore did not assess the claimed combination of mRNA booster doses, particularly fourth doses, and Omicron outcomes; this paper alone cannot establish what every other review assessed. (LLM, conf=0.91)
- Supportedcites [17] Ssentongo, 2022, SARS-Cov-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis, BMC Infect Dis sourceExperimental — accuracy not yet measured
The cited paper is a systematic review and meta-analysis of COVID-19 vaccine effectiveness. Its Results describe studies following primary vaccination, and its Discussion says the analysis was conducted before Omicron emerged. It therefore supports the citing sentence’s use of this paper as an example of a review that did not assess fourth-dose protection against Omicron outcomes; it does not, by itself, establish the claim about every published review. (LLM, conf=0.88)
- Partly supportedcites [18] Mohammed, 2023, A systematic review and meta-analysis on the real-world effectiveness of COVID-19 vaccines against infection, symptomatic and severe COVID-19 disease caused by the Omicron variant, Vaccines (Basel) sourceExperimental — accuracy not yet measured
The Results (§3.2.6–3.2.7) assess the magnitude and duration of first-booster protection and report fourth-dose effectiveness for infection, symptomatic infection, and severe outcomes. The fourth-dose estimates cover only approximately seven days, with no effectiveness data for other time periods; the sublineage analysis (§3.5) concerns the first booster, not the fourth. Thus this review leaves the claimed comprehensive fourth-dose assessment incomplete, but it does not support the broader suggestion that published reviews had not assessed booster protection across these outcomes. (LLM, conf=0.85)
- Partly supportedcites [19] Külper-Schiek, 2022, Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? third interim analysis of a living systematic review, Front Immunol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [20] Guo, 2023, Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis, Am J Infect Control source
- Supportedcites [21] Pratama, 2022, Effectiveness of COVID-19 vaccines against SARS-Cov-2 Omicron variant (B. 1.1. 529): a systematic review with meta-analysis and meta-regression, Vaccines (Basel) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [22] Zou, 2022, The vaccine efficacy against the SARS-Cov-2 Omicron: a systemic review and meta-analysis, Front Public Health sourceExperimental — accuracy not yet measured
The Introduction and Results identify this paper as a review and meta-analysis of COVID-19 vaccine effectiveness against Omicron, supporting its inclusion among the published reviews cited in the sentence. Its Results examine three-dose booster protection against infection; the broader statement about gaps across all published reviews is not attributed to this paper alone. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent evidence has shown a rapid decline in antibody titres over time following booster doses of mRNA vaccines.16”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Introduction
What the sources say
- Supportedcites [16] Lassaunière, 2022, Neutralizing antibodies against the SARS-Cov-2 Omicron variant (BA.1) 1 to 18 weeks after the second and third doses of the BNT162b2 mRNA vaccine, JAMA Netw Open source
The Results report that neutralizing antibody titers declined rapidly after the third dose of the BNT162b2 mRNA vaccine, falling 4.9- to 5.6-fold between weeks 3 and 8 across the tested variants. The Discussion likewise describes a rapid decline a few weeks after the third dose. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“protection against infection starts to wane within a few months of administration.8–11”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Introduction
What the sources say
- Supportedcites [8] Israel, 2021, Elapsed time since BNT162b2 vaccine and risk of SARS-Cov-2 infection: test negative design study, BMJ source
The Discussion’s Conclusions state that protection against SARS-CoV-2 infection from two doses of the BNT162b2 mRNA vaccine decreased after several months. The Results report higher infection odds beginning 90–119 days after the second dose than within the first 90 days. (LLM, conf=0.91)
- Partly supportedcites [9] Thomas, 2021, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (Efficacy; page not provided) show that BNT162b2 efficacy against Covid-19 declined from 96.2% within two months after the second dose to 90.1% at two to four months and 83.7% thereafter. This supports waning within a few months, but the measured outcome was Covid-19, not SARS-CoV-2 infection generally, and the study evaluated one mRNA vaccine rather than mRNA vaccines as a class. (LLM, conf=0.88)
- Not checked yetcites [10] doi:10.1016/s0140-6736(21)02183-8/attachment/e998365a-8f41-4c9c-997b-8f5a40d3aad4/mmc1.pdf
- Supportedcites [11] source
The Results (page unavailable) report declining effectiveness against SARS-CoV-2 infection between one and six months after the final vaccine dose, including analyses of both Pfizer–BioNTech and Moderna mRNA vaccines. This supports the claim that protection against infection wanes in the months following the primary series. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A recent study conducted in Japan80 reported high-level protection against Omicron infection by an mRNA booster dose (74% at 14 days after the third dose), which is consistent with our findings.”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Discussion
What the sources say
- Partly supportedcites [80] Arashiro, 2023, Coronavirus disease 19 (COVID-19) vaccine effectiveness against symptomatic severe acute respiratory syndrome Coronavirus 2 (SARS-Cov-2) infection during Delta-dominant and Omicron-dominant periods in Japan: A multicenter prospective case-control study (factors associated with SARS-Cov-2 infection and the effectiveness of COVID-19 vaccines study), Clin Infect Dis sourceExperimental — accuracy not yet measured
The Results (p. 1) report 74% vaccine effectiveness at 14 or more days after dose 3, and the Discussion (p. 7) describes protection after three doses as high. The estimate is for symptomatic SARS-CoV-2 infection during an Omicron-dominant period, rather than confirmed Omicron infections specifically; it also covers all time from day 14 onward, not only day 14. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the third-dose VE against hospitalisation was higher, with an estimated VE of 65.35% (95% CI 53.10% to 77.60%, I2=96.26%, moderate certainty) at ≥7 days after the third-dose vaccination.”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Results > Protection of third-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: compared with the primary series
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
66 more claims
Create a free account to see all 111 claims and to verify the 2 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 16
- The quote only partly states this claim. 7
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Results > Protection of third-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: compared with no vaccination
“Thirteen studies”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Results > Protection of third-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: compared with no vaccination
“32–34 36 44 45 48 51 54 55 71”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Results > Protection of third-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: compared with no vaccination
“40.58% (95% CI 34.39% to 46.74%, I2=97.04%, low certainty) at ≥120 days”
§ Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis > Results > Protection of third-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: compared with the primary series
“| | | ≥120 days | 1 study | 40.56 (34.39 to 46.74) | Low | *§ |”
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329 · cited 1×
“Disagreements were resolved through discussion or by a third reviewer, when required.”
BackgroundCochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · International Journal of Surgery · doi:10.1016/j.ijsu.2021.105906 · Cited by 11,748
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02183-8 · Cited by 1,167
Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02249-2 · Cited by 860
PROSPERO: An International Register of Systematic Review Protocols
Schiavo, J. H. (2019) · Medical Reference Services Quarterly · doi:10.1080/02763869.2019.1588072 · Cited by 643 · cited 1×
“Using an extensive search strategy described in online supplemental table 1, we searched the following electronic databases from the inception of the COVID-19 pandemic to December 2022: PubMed, Embase, CENTRAL, MEDLINE, CINAHL PLUS, APA PsycINFO, Web of Science, Scopus and ScienceDirect.”
MethodAccorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., & Gray, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119270 · Cited by 600
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435
Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
(2022) · doi:10.1056/nejmoa2201570 · Cited by 376
Buchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.32760 · Cited by 356
Chung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S. E., Chen, B., Calzavara, A., Fell, D. B., Austin, P. C., et al. (2021) · BMJ · doi:10.1136/bmj.n1943 · Cited by 307
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Magen, O., Waxman, J. G., Makov-Assif, M., Vered, R., Dicker, D., Hernán, M. A., Lipsitch, M., Reis, B. Y., Balicer, R. D., & Dagan, N. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201688 · Cited by 279
Ssentongo, P., Ssentongo, A. E., Voleti, N., Groff, D., Sun, A., Ba, D. M., Nunez, J., Parent, L. J., Chinchilli, V. M., & Paules, C. I. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07418-y · Cited by 260
Sheikh, A., Kerr, S., Woolhouse, M., McMenamin, J., Robertson, C., Simpson, C. R., Millington, T., Shi, T., Agrawal, U., Shahul Hameed, S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00141-4 · Cited by 239
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30895-3 · Cited by 228
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
Kirsebom, F. C. M., Andrews, N., Stowe, J., Toffa, S., Sachdeva, R., Gallagher, E., Groves, N., O'Connell, A.-M., Chand, M., Ramsay, M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00309-7 · Cited by 182
Klein, N. P., Stockwell, M. S., Demarco, M., Gaglani, M., Kharbanda, A. B., Irving, S. A., Rao, S., Grannis, S. J., Dascomb, K., Murthy, K., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7109e3 · Cited by 179
Tenforde, M. W., Self, W. H., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7112e1 · Cited by 170
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
Israel, A., Merzon, E., Schäffer, A. A., Shenhar, Y., Green, I., Golan-Cohen, A., Ruppin, E., Magen, E., & Vinker, S. (2021) · BMJ · doi:10.1136/bmj-2021-067873 · Cited by 170
Stowe, J., Andrews, N., Kirsebom, F., Ramsay, M., & Bernal, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33378-7 · Cited by 166
Fleming-Dutra, K. E., Britton, A., Shang, N., Derado, G., Link-Gelles, R., Accorsi, E. K., Smith, Z. R., Miller, J., Verani, J. R., & Schrag, S. J. (2022) · JAMA · doi:10.1001/jama.2022.7493 · Cited by 149
(2022) · doi:10.1038/s41591-022-01832-0 · Cited by 148
Gram, M. A., Emborg, H.-D., Schelde, A. B., Friis, N. U., Nielsen, K. F., Moustsen-Helms, I. R., Legarth, R., Lam, J. U. H., Chaine, M., Malik, A. Z., et al. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1003992 · Cited by 146
(2022) · doi:10.1136/bmj-2022-071502 · Cited by 144
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30884-6 · Cited by 143
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · doi:10.1101/2022.02.25.22271494 · Cited by 143
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 140
(2022) · doi:10.1038/s41467-022-31838-8 · Cited by 135
Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115
Plumb, I. D., Feldstein, L. R., Barkley, E., Posner, A. B., Bregman, H. S., Hagen, M. B., & Gerhart, J. L. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7115e2 · Cited by 100
Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87
(2021) · doi:10.1101/2021.12.23.21268177 · Cited by 87
(2022) · doi:10.1016/j.ebiom.2022.104042 · Cited by 87
Monge, S., Rojas-Benedicto, A., Olmedo, C., Mazagatos, C., José Sierra, M., Limia, A., Martín-Merino, E., Larrauri, A., Hernán, M. A., Moreno, D., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00292-4 · Cited by 81
Arashiro, T., Arima, Y., Muraoka, H., Sato, A., Oba, K., Uehara, Y., Arioka, H., Yanai, H., Kuramochi, J., Ihara, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac635 · Cited by 70
Self-citation(2023) · Saudi Medical Journal · doi:10.15537/1658-3175.8148 · Cited by 70
Šmíd, M., Berec, L., Přibylová, L., Májek, O., Pavlík, T., Jarkovský, J., Weiner, J., Barusová, T., & Trnka, J. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac161 · Cited by 67
Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2
Šmíd, M., Berec, L., Májek, O., Pavlík, T., Jarkovský, J., Weiner, J., Přibylová, L., Barusová, T., & Trnka, J. (2022) · doi:10.1101/2022.02.24.22271396 · Cited by 67
Auvigne, V., Vaux, S., Strat, Y. L., Schaeffer, J., Fournier, L., Tamandjou, C., Montagnat, C., Coignard, B., Levy-Bruhl, D., & Parent du Châtelet, I. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101455 · Cited by 63
Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
Accorsi, E. K., Britton, A., Shang, N., Fleming-Dutra, K. E., Link‐Gelles, R., Smith, Z., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2203165 · Cited by 59
Lassaunière, R., Polacek, C., Frische, A., Boding, L., Sækmose, S. G., Rasmussen, M., & Fomsgaard, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12073 · Cited by 55
Butt, A. A., Talisa, V. B., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac328 · Cited by 53
Suah, J. L., Tng, B. H., Tok, P. S. K., Husin, M., Thevananthan, T., Peariasamy, K. M., & Sivasampu, S. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2072773 · Cited by 53
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis
Zou, Y., Huang, D., Jiang, Q., Guo, Y., & Chen, C. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.940956 · Cited by 52 · cited 1×
“…the VE of third-dose and fourth-dose mRNA vaccines against SARS- CoV-2 Omicron subvariant infection and symptomatic infection wanes over time; however, it offers substantial protection for at least 6 months against severe COVID-19 outcomes, although the duration of protection remains uncertain.”
Background(2022) · doi:10.1001/jamanetworkopen.2022.24657 · Cited by 51
Muhsen, K., Maimon, N., Mizrahi, A., Boltyansky, B., Bodenheimer, O., Diamant, Z. H., Gaon, L., Cohen, D., & Dagan, R. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.2658 · Cited by 50
Björk, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Inghammar, M., & Kahn, F. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.18.2200322 · Cited by 47
Natarajan, K., Prasad, N., Dascomb, K., Irving, S. A., Yang, D.-H., Gaglani, M., Klein, N. P., DeSilva, M. B., Ong, T. C., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7113e2 · Cited by 47
Prasad, N., Derado, G., Nanduri, S. A., Reses, H. E., Dubendris, H., Wong, E., Soe, M. M., Li, Q., Dollard, P., Bagchi, S., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7118a4 · Cited by 47
Mohammed, H., Pham-Tran, D. D., Yeoh, Z. Y. M., Wang, B., McMillan, M., Andraweera, P. H., & Marshall, H. S. (2023) · Vaccines · doi:10.3390/vaccines11020224 · Cited by 47
(2022) · doi:10.3389/fimmu.2022.905585 · Cited by 46
Külper-Schiek, W., Piechotta, V., Pilic, A., Batke, M., Dreveton, L.-S., Geurts, B., Koch, J., Köppe, S., Treskova, M., Vygen-Bonnet, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940562 · Cited by 44 · cited 1×
“…the VE of third-dose and fourth-dose mRNA vaccines against SARS- CoV-2 Omicron subvariant infection and symptomatic infection wanes over time; however, it offers substantial protection for at least 6 months against severe COVID-19 outcomes, although the duration of protection remains uncertain.”
BackgroundProtection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
Yoon, S. K., Hegmann, K. T., Thiese, M. S., Burgess, J. L., Ellingson, K., Lutrick, K., Olsho, L. E. W., Edwards, L. J., Sokol, B., Caban-Martinez, A. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201821 · Cited by 41
Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients
(2022) · doi:10.1016/j.ekir.2022.04.005 · Cited by 38
(2022) · doi:10.1136/bmjopen-2022-063935 · Cited by 37
(2022) · doi:10.1093/cid/ciac501 · Cited by 35
Martellucci, C. A., Flacco, M. E., Soldato, G., Martino, G. D., Carota, R., Caponetti, A., & Manzoli, L. (2022) · Vaccines · doi:10.3390/vaccines10050662 · Cited by 34
Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy.
Hightower, A. W., Orenstein, W. A., & Martin, S. M. (1988) · Europe PMC (PubMed Central) · Cited by 32
Pratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30
Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents
(2022) · doi:10.1542/peds.2022-057634 · Cited by 27
Richterman, A., Behrman, A., Brennan, P. J., O’Donnell, J. A., Snider, C. K., & Chaiyachati, K. H. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac454 · Cited by 24
Tai, C. G.-L., Maragakis, L. L., Connolly, S., DiFiori, J. P., Anderson, D. J., Grad, Y. H., & Mack, C. D. (2022) · JAMA · doi:10.1001/jama.2022.9479 · Cited by 24
Butt, A. A., Talisa, V. B., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac178 · Cited by 21
Bestvina, C. M., Whisenant, J. G., Torri, V., Cortellini, A., Wakelee, H. A., Peters, S., Roca, E., Toma, A. D., Hirsch, F. R., Mamdani, H. M., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100335 · Cited by 20
Ashby, D. R., Caplin, B., Corbett, R., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac209 · Cited by 19
Meggiolaro, A., Sane Schepisi, M., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2130773 · Cited by 17 · cited 1×
“…the VE of third-dose and fourth-dose mRNA vaccines against SARS- CoV-2 Omicron subvariant infection and symptomatic infection wanes over time; however, it offers substantial protection for at least 6 months against severe COVID-19 outcomes, although the duration of protection remains uncertain.”
BackgroundSharma, A., Oda, G., & Holodniy, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac325 · Cited by 17
Guo, K., Ni, P., Chang, S., Jin, Y., Duan, G., & Zhang, R. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.005 · Cited by 12 · cited 1×
“…the VE of third-dose and fourth-dose mRNA vaccines against SARS- CoV-2 Omicron subvariant infection and symptomatic infection wanes over time; however, it offers substantial protection for at least 6 months against severe COVID-19 outcomes, although the duration of protection remains uncertain.”
BackgroundAuthor Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01818-y · Cited by 4
Research works printed but not linked: 3
- 10.1016/S0140-6736(21)02183-8/ATTACHMENT/E998365A-8F41-4C9C-997B-8F5A40D3AAD4/MMC1.PDF · doi:10.1016/s0140-6736(21)02183-8/attachment/e998365a-8f41-4c9c-997b-8f5a40d3aad4/mmc1.pdf
- 10.1016/S0140-6736(21)02249-2/ATTACHMENT/588607F0-89F7-4E80-8E48-FB7CE8C7F7EC/MMC1.PDF · doi:10.1016/s0140-6736(21)02249-2/attachment/588607f0-89f7-4e80-8e48-fb7ce8c7f7ec/mmc1.pdf
- World Health Organization . WHO SAGE roadmap on uses of COVID-19 vaccines in the context of Omicron and substantial population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when Omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, update: 21 January 2022, latest update: 30 March 2023. 2023.
Cited by
Clark, J. J., Hoxie, I., Adelsberg, D. C., Sapse, I. A., Andreata‐Santos, R., Yong, J. S., Amanat, F., Tcheou, J., Raskin, A. J., Singh, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114922 · Cited by 47
Quarleri, J. F., Delpino, M. V., & Galván, V. (2024) · GeroScience · doi:10.1007/s11357-024-01066-7 · Cited by 27
“Over 90% of the global human population has likely encountered infection with at least one Omicron subvariant, a phenomenon exacerbated by the absence of robust and enduring protection against novel viral acquisitions offered by prior infections or vaccinations [7–10].”
Paul-Chima, U. O., Okon, M. B., Ogenyi Fabian, C., Nnenna, U. J., & Ugwu, C. N. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2661120 · Cited by 22
Clark, J. J., Hoxie, I., Adelsberg, D. C., et al. (2024) · bioRxiv · doi:10.1101/2024.02.28.582613 · Cited by 15
“…a larger number of non-59 neutralizing antibodies than infection 15 , and that despite the well-documented loss of neutralizing activity against recently arisen variants of concern (VOCs), individuals vaccinated with the BNT162b2 and mRNA-61 1273 vaccines still exhibit protection from disease 16 .”
Šmíd, M., Barusová, T., Jarkovský, J., Májek, O., Pavlík, T., Přibylová, L., Weinerová, J., Zajíček, M., & Trnka, J. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.35.2300690 · Cited by 11
Metadata
- Authors
- Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., Ota, E., & Suzuki, M.
- Affiliations
- Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
- National Institute of Infectious Diseases (JP)
- National Center for Global Health and Medicine (JP)
- Graduate School of Public Health, St Luke's International University, Chuo-ku, Tokyo, Japan
- University of Rajshahi (BD)
- St. Luke's International University (JP)
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2023-12
- Volume
- 13
- Issue
- 12
- Pages
- e076892
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC10748972
- OpenAlex
- W4390055705
- Semantic Scholar
- 6bc87b18e398c70e223201c97dd4f38dab4d3447
- Cited by
- 29
- References
- 95
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 12
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Ministry of Health, Labour and Welfare (23HA2005, 23HA2017)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2 Omicron subvariants, mRNA vaccines, third dose, vaccine effectiveness, waning immunity, BA.1, BA.2, BA.3, BA.4, BA.5, severe COVID-19 outcomes, breakthrough infection, Omicron subvariants, vaccine durability
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.